Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts
Rhea-AI Summary
Aclarion (Nasdaq: ACON, ACONW) published a CEO shareholder letter outlining 2026 priorities: expand adoption of the Nociscan platform, pursue reimbursement with U.S. regional insurers, grow clinical evidence, and advance commercial engagement with physicians and imaging centers.
The company highlighted an initial CLARITY trial readout in Q4 2026 and a strong balance sheet with cash runway into 2028 to support execution of these catalysts.
Positive
- Initial CLARITY readout scheduled for Q4 2026
- Cash runway available into 2028
- Expanding commercial engagement with physicians and imaging centers
- Advancing reimbursement initiatives in the UK and US
Negative
- Broader payer adoption depends on securing reimbursement from regional US insurers
- Clinical and commercial progress hinges on the pending CLARITY readout in Q4 2026
News Market Reaction – ACONW
In the Mar 19 session, ACONW gained 0.30%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Conference participation | Positive | +28.7% | ROTH Conference meetings on Nociscan progress and strong balance sheet. |
| Mar 12 | Investor meetings | Positive | +8.1% | CEO attendance at LSI USA 2026 to meet investors and partners. |
| Feb 05 | Shareholder letter | Positive | +3.1% | 2026 priorities, CLARITY timelines, and cash runway into 2028. |
| Feb 03 | Commercial expansion | Positive | -2.2% | Adding Source Healthcare to expand Nociscan use and evidence. |
| Jan 13 | Financing & runway | Positive | -6.2% | Common-stock financing that strengthened cash to support CLARITY and growth. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Aclarion news has generally been positive, with three of the last five announcements seeing positive next-day price reactions and two drawing negative reactions, indicating mixed but often constructive responses to updates on strategy, financing, and Nociscan adoption.
Over the last few months, Aclarion has highlighted balance sheet strengthening, clinical progress, and commercial expansion. A $10.4 million financing in Jan 2026 extended cash runway into 2028. Subsequent news emphasized Nociscan adoption, CLARITY trial enrollment, and investor outreach, including conference participation and a prior 2026 shareholder letter. Those updates often produced positive warrant reactions, so today’s CEO letter continues a pattern of communication around strategic catalysts, cash runway, and reimbursement progress.
Key Terms
reimbursement coverage financial
biomarkers medical
augmented intelligence (ai) algorithms technical
clinical trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption
Initial CLARITY trial readout in Q4 2026
Strong Balance Sheet with Cash Runway into 2028
BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company’s recent momentum and value-creating priorities for 2026.
The letter highlights Aclarion’s continued momentum in expanding adoption of its Nociscan platform, growing clinical evidence, and advancing reimbursement initiatives in both the United Kingdom and the United States. The update also highlights the company’s ongoing CLARITY clinical trial, expansion of commercial engagement with physicians and imaging centers, and its strong balance sheet supporting continued execution.
“Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business,” said Brent Ness, Chief Executive Officer of Aclarion. “With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders.”
The full CEO Shareholder Letter is available on the company’s website.
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, an initial interim data readout is expected later in 2026, followed by the public disclosure of early interim results, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
